Evogene (EVGN) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Evogene’s subsidiary, Lavie Bio, faces a strategic shift as Corteva Agriscience terminates their licensing agreement for bio-fungicide candidates. Despite this setback, Lavie Bio will retain rights to the technology and plans to advance its bio-fungicide pipeline independently. Other collaborations between Lavie Bio and Corteva remain unaffected.
For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue